DIMERIX INVESTOR CALL & PRESENTATION

Potential value driving events 2021 2022 clinical DMX-200 demonstrated encouraging efficacy and strong safety profile across multiple Phase 2 renal clinical studies Consistent advice received from FDA, EMA and UK MHRA on FSGS Phase 3 study design Orphan Drug Designation/accelerated approval pathway granted by US FDA, EU EMA and UK MHRA for FSGS Two independent Phase 3 clinical studies underway in patients with COVID-19 respiratory complications DMX-200 manufacturing process optimised to improve commercial scalability and global logistics DMX-700 in COPD progressed further towards clinical development Expansion of IP portfolio Strong financial position Dimerix FSGS ethics approval and clinical site initiations FSGS Phase 3 study recruitment and first patient first dose REMAP-CAP Phase 3 COVID-19 study recruitment and top line data CLARITY 2.0 Phase 3 COVID-19 study recruitment and top line data DMX-700 for Chronic Obstructive Pulmonary Disease progression towards clinical study Diabetic kidney disease clinical study design and next steps Further expansion of IP portfolio FSGS Phase 3 study Part 1 analysis and progression to Part 2 13

View entire presentation